Inhibition of Taq polymerase as a method for screening heparin for oversulfated contaminants

被引:38
作者
Tami, Cecilia [1 ]
Puig, Montserrat [1 ]
Reepmeyer, John C. [2 ]
Ye, Hongping [2 ]
D'Avignon, D. Andre [3 ]
Buhse, Lucinda [2 ]
Verthelyi, Daniela [1 ]
机构
[1] US FDA, Ctr Drug Evaluat & Res, Off Biotechnol Prod, Lab Immunol,Div Therapeut Prod, Bethesda, MD 20892 USA
[2] US FDA, Ctr Drug Evaluat & Res, Div Pharmaceut Anal, Bethesda, MD 20892 USA
[3] Washington Univ, Dept Chem, St Louis, MO 63130 USA
关键词
Heparin; Oversulfated chondroitin sulfate; Glycosaminoglycan; Taq polymerase; PCR; Safety;
D O I
10.1016/j.biomaterials.2008.08.024
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Heparin and low molecular heparins are extensively used in the treatment of a wide range of diseases in addition to their classic anticoagulant activity and can be found coating medical devices Such as catheters, stents and filters. Early in 2008, a sharp increase in heparin-associated severe adverse events, including over 80 deaths, was linked to the presence of a contaminant identified as hypersulfated chondroitin sulfate (OS-CS). OS-CS is one of several oversulfated glycosaminoglycans (GAGs) of different origins that can potentially Cause similar clinical problems underscoring the need to develop robust screening methods for contaminants in existing and future lots of heparin. This study demonstrates that oversulfated GAGs block the activity of Taq polymerase used for real time PCR. Based on this finding we developed a simple, rapid, sensitive and high throughput screening method to detect and quantify oversulfated chondroitin sulfate (OS-CS) and other potential oversulfated contaminants in commercial lots of heparin. This method requires less than 100 miliUnits (mU) of heparin as starting material, therefore avoiding the need to lyophilize and concentrate samples, and has a limit of detection of < 1 ng for all oversulfated GAGs tested. Published by Elsevier Ltd.
引用
收藏
页码:4808 / 4814
页数:7
相关论文
共 19 条
[1]   Heparin induced thrombocytopenia thrombosis (HIT/T) syndrome: diagnosis and treatment [J].
Baglin, TP .
JOURNAL OF CLINICAL PATHOLOGY, 2001, 54 (04) :272-274
[2]   Enzymatic redesigning of biologically active heparan sulfate [J].
Chen, JH ;
Avci, FY ;
Muñoz, EM ;
McDowell, LM ;
Chen, M ;
Pedersen, LC ;
Zhang, LJ ;
Linhardt, RJ ;
Liu, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (52) :42817-42825
[3]   Neuroprotective properties of glycosaminoglycans: Potential treatment for neurodegenerative disorders [J].
Dudas, B. ;
Rose, M. ;
Cornelli, U. ;
Pavlovich, A. ;
Hanin, I. .
NEURODEGENERATIVE DISEASES, 2008, 5 (3-4) :200-205
[4]   Heparin in tumor progression and metastatic dissemination [J].
Falanga, Anna ;
Marchetti, Marina .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2007, 33 (07) :688-694
[5]   INFLUENCES OF ANIONIC POLYSACCHARIDES ON DNA-SYNTHESIS IN ISOLATED-NUCLEI AND BY DNA POLYMERASE-ALPHA - CORRELATION OF OBSERVED EFFECTS WITH PROPERTIES OF THE POLYSACCHARIDES [J].
FURUKAWA, K ;
BHAVANANDAN, VP .
BIOCHIMICA ET BIOPHYSICA ACTA, 1983, 740 (04) :466-475
[6]   HEPARIN-ASSOCIATED THROMBOCYTOPENIA IN A PATIENT TREATED WITH POLYSULFATED CHONDROITIN SULFATE - EVIDENCE FOR IMMUNOLOGICAL CROSS-REACTIVITY BETWEEN HEPARIN AND POLYSULFATED GLYCOSAMINOGLYCAN [J].
GREINACHER, A ;
MICHELS, I ;
SCHAFER, M ;
KIEFEL, V ;
MUELLERECKHARDT, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1992, 81 (02) :252-254
[7]  
Guerrini M., 2008, NAT BIOTECHNOL
[8]   INHIBITION OF HUMAN-IMMUNODEFICIENCY-VIRUS GENE AMPLIFICATION BY HEPARIN [J].
HOLODNIY, M ;
KIM, S ;
KATZENSTEIN, D ;
KONRAD, M ;
GROVES, E ;
MERIGAN, TC .
JOURNAL OF CLINICAL MICROBIOLOGY, 1991, 29 (04) :676-679
[9]  
IZRAELI S, 1991, NUCLEIC ACIDS RES, V19, P6051
[10]   Regulators scramble to tighten loopholes after heparin debacle [J].
Jia, Hepeng .
NATURE BIOTECHNOLOGY, 2008, 26 (05) :477-478